Dickason David 4
4 · RespireRx Pharmaceuticals Inc. · Filed Oct 6, 2020
Insider Transaction Report
Form 4
Dickason David
SVP of Pre-Clinical Prod. Dev.
Transactions
- Award
Common Stock Options (to purchase shares of Common Stock)
2020-09-30+2,000,000→ 2,000,000 totalExercise: $0.01Exp: 2025-09-30→ Common Stock (2,000,000 underlying)
Footnotes (1)
- [F1]These Common Stock Options vest in four equal installments: 25 percent on December 31, 2020, 25 percent on March 31, 2021, 25 percent on June 30, 2021, and 25 percent on September 30, 2021.